Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic disease. Tumors are
poorly immunogenic and immunosuppressive, preventing T cell activation in the tumor …

Agents that remodel the tumor microenvironment (TME), prime functional tumor-specific T
cells, and block inhibitory signaling pathways are essential components of effective …

Background & Aims Premalignant lesions and early stage tumors contain
immunosuppressive microenvironments that create barriers for cancer vaccines. Kras …

Most cancer vaccines induce CTL responses to tumor-associated antigens (TAA). Killing of
tumor cells occurs through TAA-specific CTL-mediated cytolysis. Here, we show that one …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

Pancreatic cancer is resistant to conventional therapeutic interventions, mainly due to
abundant cancer stromal cells and poor immune cell infiltration. Here, we used a targeted …

The facultative intracellular bacterium Listeria monocytogenes is being developed as a
cancer vaccine platform because of its ability to induce potent innate and adaptive immunity …

For over a century, inactivated or attenuated bacteria have been employed in the clinic as
immunotherapies to treat cancer, starting with the Coley's vaccines in the 19th century and …

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy resistant to therapies,
including immune-checkpoint blockade. We investigated two distinct strategies to modulate …

Pancreatic ductal adenocarcinomas (PDAs) erect physical barriers to chemotherapy and
induce multiple mechanisms of immune suppression, creating a sanctuary for unimpeded …